MX2022013499A - Bibliotecas de ácidos nucleicos variantes para coronavirus. - Google Patents

Bibliotecas de ácidos nucleicos variantes para coronavirus.

Info

Publication number
MX2022013499A
MX2022013499A MX2022013499A MX2022013499A MX2022013499A MX 2022013499 A MX2022013499 A MX 2022013499A MX 2022013499 A MX2022013499 A MX 2022013499A MX 2022013499 A MX2022013499 A MX 2022013499A MX 2022013499 A MX2022013499 A MX 2022013499A
Authority
MX
Mexico
Prior art keywords
libraries
nucleic acid
acid libraries
coronavirus
variant nucleic
Prior art date
Application number
MX2022013499A
Other languages
English (en)
Inventor
Qiang Liu
Aaron Sato
Tom Yuan
Original Assignee
Twist Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twist Bioscience Corp filed Critical Twist Bioscience Corp
Publication of MX2022013499A publication Critical patent/MX2022013499A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En el presente documento se proporcionan métodos y composiciones relacionados con bibliotecas de anticuerpos optimizados que tienen ácidos nucleicos que codifican para un anticuerpo que comprende secuencias modificadas. Las bibliotecas descritas en el presente documento comprenden ácidos nucleicos que codifican para anticuerpos contra el SARS-CoV-2 o ACE2. En el presente documento se describen además bibliotecas de proteínas generadas cuando se traducen las bibliotecas de ácidos nucleicos. En el presente documento se describen adicionalmente bibliotecas de células que expresan bibliotecas de ácidos nucleicos variegadas descritas en el presente documento.
MX2022013499A 2020-04-27 2021-04-27 Bibliotecas de ácidos nucleicos variantes para coronavirus. MX2022013499A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063016254P 2020-04-27 2020-04-27
US202063034896P 2020-06-04 2020-06-04
US202063069665P 2020-08-24 2020-08-24
US202063073362P 2020-09-01 2020-09-01
US202063104465P 2020-10-22 2020-10-22
US202063115568P 2020-11-18 2020-11-18
PCT/US2021/029486 WO2021222316A2 (en) 2020-04-27 2021-04-27 Variant nucleic acid libraries for coronavirus

Publications (1)

Publication Number Publication Date
MX2022013499A true MX2022013499A (es) 2023-01-16

Family

ID=78374237

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022013499A MX2022013499A (es) 2020-04-27 2021-04-27 Bibliotecas de ácidos nucleicos variantes para coronavirus.
MX2022013513A MX2022013513A (es) 2020-04-27 2021-04-27 Bibliotecas de ácidos nucleicos variantes para coronavirus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013513A MX2022013513A (es) 2020-04-27 2021-04-27 Bibliotecas de ácidos nucleicos variantes para coronavirus.

Country Status (11)

Country Link
US (2) US20210395344A1 (es)
EP (2) EP4142739A2 (es)
JP (2) JP2023523336A (es)
KR (2) KR20230017781A (es)
CN (2) CN116113420A (es)
AU (2) AU2021263755A1 (es)
BR (2) BR112022021789A2 (es)
CA (2) CA3177029A1 (es)
IL (2) IL297700A (es)
MX (2) MX2022013499A (es)
WO (2) WO2021222315A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409139B2 (en) 2013-08-05 2016-08-09 Twist Bioscience Corporation De novo synthesized gene libraries
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
AU2016324296A1 (en) 2015-09-18 2018-04-12 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
US11512347B2 (en) 2015-09-22 2022-11-29 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
WO2018057526A2 (en) 2016-09-21 2018-03-29 Twist Bioscience Corporation Nucleic acid based data storage
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
US10696965B2 (en) 2017-06-12 2020-06-30 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
EP3681906A4 (en) 2017-09-11 2021-06-09 Twist Bioscience Corporation GPCR-BINDING PROTEINS AND THEIR SYNTHESIS
GB2583590A (en) 2017-10-20 2020-11-04 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
SG11202011467RA (en) 2018-05-18 2020-12-30 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
KR20210143766A (ko) 2019-02-26 2021-11-29 트위스트 바이오사이언스 코포레이션 Glp1 수용체에 대한 변이체 핵산 라이브러리
WO2020176680A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CA3144644A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2023523336A (ja) * 2020-04-27 2023-06-02 ツイスト バイオサイエンス コーポレーション コロナウイルス用の変異体核酸ライブラリー
US20220348659A1 (en) * 2021-03-24 2022-11-03 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
WO2023091614A2 (en) * 2021-11-18 2023-05-25 Twist Bioscience Corporation Dickkopf-1 variant antibodies and methods of use
WO2023102034A2 (en) * 2021-12-01 2023-06-08 Twist Bioscience Corporation Neuropilin-1 variant antibodies and methods of use
US20230257448A1 (en) * 2022-01-03 2023-08-17 Twist Bioscience Corporation Bispecific sars-cov-2 antibodies and methods of use
WO2023235827A2 (en) * 2022-06-03 2023-12-07 The Rockefeller University Coronavirus-inhibiting antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US9403904B2 (en) * 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
TWI609882B (zh) * 2012-05-22 2018-01-01 必治妥美雅史谷比公司 雙特異性抗體及其使用方法
EP3565839A4 (en) * 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
CA3062825A1 (en) * 2017-05-08 2018-11-15 Adimab, Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
JP2023523336A (ja) * 2020-04-27 2023-06-02 ツイスト バイオサイエンス コーポレーション コロナウイルス用の変異体核酸ライブラリー
US20220206001A1 (en) * 2020-10-22 2022-06-30 Twist Bioscience Corporation Methods and systems for detecting coronavirus
US20230002478A1 (en) * 2021-06-22 2023-01-05 Twist Bioscience Corporation Methods and compositions relating to covid antibody epitopes

Also Published As

Publication number Publication date
AU2021263756A1 (en) 2022-12-15
CN116113420A (zh) 2023-05-12
WO2021222316A2 (en) 2021-11-04
MX2022013513A (es) 2023-01-16
JP2023523336A (ja) 2023-06-02
IL297700A (en) 2022-12-01
BR112022021780A2 (pt) 2023-03-07
CN116209463A (zh) 2023-06-02
EP4142784A2 (en) 2023-03-08
US20210355194A1 (en) 2021-11-18
AU2021263755A1 (en) 2022-12-15
EP4142739A2 (en) 2023-03-08
WO2021222316A3 (en) 2021-12-09
WO2021222315A2 (en) 2021-11-04
BR112022021789A2 (pt) 2023-03-07
JP2023523335A (ja) 2023-06-02
KR20230016184A (ko) 2023-02-01
IL297701A (en) 2022-12-01
CA3177029A1 (en) 2021-11-04
US20210395344A1 (en) 2021-12-23
CA3177030A1 (en) 2021-11-04
WO2021222315A3 (en) 2021-12-09
KR20230017781A (ko) 2023-02-06

Similar Documents

Publication Publication Date Title
MX2022013499A (es) Bibliotecas de ácidos nucleicos variantes para coronavirus.
WO2022271884A3 (en) Methods and compositions relating to covid antibody epitopes
WO2023023190A3 (en) Single domain antibodies for sars-cov-2
WO2023023183A3 (en) Sars-cov-2 antibodies and related compositions and methods of use
Li et al. Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation
Sieh et al. Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis
ATE514783T1 (de) Plasmidsystem zur expression mehrerer gene
MX2022006995A (es) Bibliotecas de acidos nucleicos variantes para receptores de adenosina.
CL2010001427A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
ATE498011T1 (de) Modifizierte embryonale stammzellen und embryonales stammzellspezifisches gen
NZ734803A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
BRPI0619579B8 (pt) Métodos para aumentar a expectativa de vida replicativa e/ou estabilidade de uma célula produtora de anticorpo, para expressar um gene de uma célula b codificando a cadeia pesada de ig e/ou cadeia leve de ig, para produzir linhagem de células b, para obter anticorpos, e, método ex vivo para produzir anticorpos capazes de especificamente ligar um antígeno de interesse
ATE458064T1 (de) Verfahren zur wirksamen rna-interferenz in säugerzellen
MX2009012609A (es) Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
AR103794A1 (es) Producción de alquenos
Foda et al. Multifunctional G-rich and RRM-containing domains of TbRGG2 perform separate yet essential functions in trypanosome RNA editing
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.
WO2023076419A3 (en) Sars-cov-2 antibodies and methods of use
ATE452137T1 (de) Verfahren und konstrukte zur expression von clostripain mit hoher ausbeute
WO2023091614A3 (en) Dickkopf-1 variant antibodies and methods of use
Churamani et al. Molecular characterization of a novel cell surface ADP-ribosyl cyclase from the sea urchin
ATE553194T1 (de) Verfahren zur dipeptidherstellung
AU2011220003A8 (en) Plants having enhanced yield-related traits and a method for making the same